Literature DB >> 15888795

Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma.

H Iida1, M Honda, H F Kawai, T Yamashita, Y Shirota, B-C Wang, H Miao, S Kaneko.   

Abstract

BACKGROUND AND AIMS: alpha-Fetoprotein (AFP), a tumour marker for hepatocellular carcinoma (HCC), is associated with poor prognosis. Using cDNA microarray analysis, we previously found that ephrin-A1, an angiogenic factor, is the most differentially overexpressed gene in AFP producing hepatoma cell lines. In the present study, we investigated the significance of ephrin-A1 expression in HCC.
METHODS: We examined ephrin-A1 expression and its effect on cell proliferation and gene expression in five AFP producing hepatoma cell lines, three AFP negative hepatoma cell lines, and 20 human HCC specimens.
RESULTS: Ephrin-A1 expression levels were lowest in normal liver tissue, elevated in cirrhotic tissue, and further elevated in HCC specimens. Ephrin-A1 expression was strongly correlated with AFP expression (r = 0.866). We showed that ephrin-A1 induced expression of AFP. This finding implicates ephrin-A1 in the mechanism of AFP induction in HCC. Ephrin-A1 promoted the proliferation of ephrin-A1 underexpressing HLE cells, and an ephrin-A1 antisense oligonucleotide inhibited the proliferation of ephrin-A1 overexpressing Huh7 cells. Thus ephrin-A1 affects hepatoma cell growth. cDNA microarray analysis showed that ephrin-A1 induced expression of genes related to the cell cycle (p21), angiogenesis (angiopoietin 1 and thrombospondin 1), and cell-cell interactions (Rho, integrin, and matrix metalloproteinases) in cultured hepatoma cells. These ephrin-A1 induced genes are also activated in HCC tissues that overexpress AFP.
CONCLUSION: These findings suggest that the poor prognosis of patients with AFP producing HCC is partially caused by ephrin-A1 expression, which induces expression of genes related to tumour cell growth, angiogenesis, invasion, and metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888795      PMCID: PMC1774523          DOI: 10.1136/gut.2004.049486

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  42 in total

1.  Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation.

Authors:  H Miao; E Burnett; M Kinch; E Simon; B Wang
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

2.  Differential gene expression between chronic hepatitis B and C hepatic lesion.

Authors:  M Honda; S Kaneko; H Kawai; Y Shirota; K Kobayashi
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

3.  alpha-fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis.

Authors:  H F Kawai; S Kaneko; M Honda; Y Shirota; K Kobayashi
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

4.  Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer.

Authors:  K Maeda; Y Nishiguchi; S M Kang; M Yashiro; N Onoda; T Sawada; T Ishikawa; K Hirakawa
Journal:  Oncol Rep       Date:  2001 Jul-Aug       Impact factor: 3.906

5.  Overexpression of the EphA2 tyrosine kinase in prostate cancer.

Authors:  J Walker-Daniels; K Coffman; M Azimi; J S Rhim; D G Bostwick; P Snyder; B J Kerns; D J Waters; M S Kinch
Journal:  Prostate       Date:  1999-12-01       Impact factor: 4.104

6.  Up-regulation of ephrin-A1 during melanoma progression.

Authors:  D J Easty; S P Hill; M Y Hsu; M E Fallowfield; V A Florenes; M Herlyn; D C Bennett
Journal:  Int J Cancer       Date:  1999-10-22       Impact factor: 7.396

7.  The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.

Authors:  K Ogawa; R Pasqualini; R A Lindberg; R Kain; A L Freeman; E B Pasquale
Journal:  Oncogene       Date:  2000-12-07       Impact factor: 9.867

8.  Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway.

Authors:  H Miao; B R Wei; D M Peehl; Q Li; T Alexandrou; J R Schelling; J S Rhim; J R Sedor; E Burnett; B Wang
Journal:  Nat Cell Biol       Date:  2001-05       Impact factor: 28.824

9.  EphA2 overexpression causes tumorigenesis of mammary epithelial cells.

Authors:  D P Zelinski; N D Zantek; J C Stewart; A R Irizarry; M S Kinch
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

10.  Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays.

Authors:  Y Shirota; S Kaneko; M Honda; H F Kawai; K Kobayashi
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

View more
  31 in total

1.  Biomimetic hydrogels with immobilized ephrinA1 for therapeutic angiogenesis.

Authors:  Jennifer E Saik; Daniel J Gould; Aakash H Keswani; Mary E Dickinson; Jennifer L West
Journal:  Biomacromolecules       Date:  2011-06-15       Impact factor: 6.988

Review 2.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

3.  Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure.

Authors:  Soraya Abouzahr; Georges Bismuth; Catherine Gaudin; Oliver Caroll; Peter Van Endert; Abdelali Jalil; Jean Dausset; Isabelle Vergnon; Catherine Richon; Audrey Kauffmann; Jérôme Galon; Graca Raposo; Fathia Mami-Chouaib; Salem Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

4.  Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B.

Authors:  Ming Zhang; Bo Li; Lu-Nan Yan; Fei Yin; Tian-Fu Wen; Yong Zeng; Ji-Chun Zhao; Yu-Kui Ma
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

5.  Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice.

Authors:  Jessica L Dries; Susan D Kent; Jitka A I Virag
Journal:  J Physiol       Date:  2011-01-31       Impact factor: 5.182

6.  Alpha-1-antitrypsin deficiency resulting in a hitherto unseen presentation of hepatocellular carcinoma: polycythemia but with normal alpha fetoprotein.

Authors:  David Ryan Owen; Ramachandran Sivakumar; Eui-Sik Suh; Murugiah Seevaratnam
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

Review 7.  Ephs and ephrins in cancer: ephrin-A1 signalling.

Authors:  Amanda Beauchamp; Waldemar Debinski
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

Review 8.  Serum tumor markers for detection of hepatocellular carcinoma.

Authors:  Lin Zhou; Jia Liu; Feng Luo
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

9.  The alpha-fetoprotein (AFP) third domain: a search for AFP interaction sites of cell cycle proteins.

Authors:  G J Mizejewski
Journal:  Tumour Biol       Date:  2016-07-22

10.  Downregulation of betaine homocysteine methyltransferase (BHMT) in hepatocellular carcinoma associates with poor prognosis.

Authors:  Bin Jin; Zhiwei Gong; Nongguo Yang; Zhaoquan Huang; Sien Zeng; Hui Chen; Sanyuan Hu; Guangdong Pan
Journal:  Tumour Biol       Date:  2015-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.